Table 4.
Univariate and multivariate analysis of RFS within 2 years.
| Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
| Gender | 162 | ||||
| Female | 37 | Reference | |||
| Male | 125 | 1.154 (0.611-2.179) | 0.658 | ||
| Age | 162 | ||||
| ≤60 | 107 | Reference | |||
| >60 | 55 | 1.104 (0.642-1.898) | 0.720 | ||
| BMI>28 | 162 | ||||
| ≤28 | 143 | Reference | |||
| >28 | 19 | 1.848 (0.873-3.916) | 0.109 | ||
| Diabetes | 162 | ||||
| No | 151 | Reference | |||
| Yes | 11 | 0.485 (0.151-1.552) | 0.222 | ||
| Drinking history | 162 | ||||
| No | 130 | Reference | |||
| Yes | 32 | 1.432 (0.795-2.578) | 0.232 | ||
| HBSAg (+) | 162 | ||||
| No | 27 | Reference | |||
| Yes | 135 | 0.748 (0.387-1.443) | 0.386 | ||
| Tumor number | 162 | ||||
| Solitary | 138 | Reference | |||
| Multiple | 24 | 0.887 (0.420-1.872) | 0.754 | ||
| Cirrhosis | 162 | ||||
| No | 26 | Reference | |||
| Yes | 136 | 0.574 (0.304-1.085) | 0.087 | ||
| AJCC Staging | 162 | ||||
| I-II | 154 | Reference | |||
| III-IV | 8 | 1.609 (0.581-4.456) | 0.360 | ||
| Postoperative treatment (Ablation or TACE) | 162 | ||||
| No | 135 | Reference | |||
| Yes | 27 | 1.274 (0.687-2.364) | 0.442 | ||
| AFP (ng/ml) | 162 | ||||
| ≤400 | 112 | Reference | |||
| >400 | 50 | 1.124 (0.649-1.946) | 0.676 | ||
| CIP | |||||
| ≤1.48 | 73 | Reference | |||
| >1.48 | 89 | 5.851 (2.770 - 12.360) | < 0.001 | 5.851 (2.770 - 12.360) | < 0.001 |
SIRI, Systemic Inflammation Response Index; PLR, Platelet-to-Lymphocyte Ratio; NLR, Neutrophil-to-Lymphocyte Ratio; SII, Systemic Immune-Inflammation Index; BMI, Body mass index; N, Regional lymph node metastasis; AFP, alpha fetoprotein.